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Background Many biological and chemical agents have the capacity to alter the way the
immune system functions in human and animals. This study evaluates the immunotoxicity
of 20 substances used widely in work environments.
Methods A systematic literature search on the immunotoxicity of 20 chemicals was per-
formed. The first step was to review literature on immunotoxicity testing and testing schemes
adopted for establishing immunotoxicity in humans. The second step consisted of providing a
documentation on immunotoxicity of substances that arewidely used inwork environment, by
building tables for each chemical of interest (benzene, trichloroethylene, PAHs, crystalline
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classification of substances; an index (strong, intermediate, weak, nil) was assigned on the
basis of the evidence of toxicity and type of immunotoxic effects (immunosuppression, auto-
immunity, hypersensitivity) on the basis of the immune responses. Finally substances were
assigned a score of immunotoxic power.
Results Tables have been produced that include information for the 20 substances of interest,
based on 227 animal studies and 94 human studies. Each substance was assigned an index of
immunotoxic evidence, a score of immunotoxic power and type of immunotoxic effect.
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INTRODUCTION
Consequences of Immunotoxicity
A number of biological or chemical agents have the
capacity to alter the functionality of the immune system in
humans and animals, potentially compromising the organism’s
ability to recognize or neutralize infectious agents or neoplastic
cells.
A number of chemical and environmental agents as well as
pharmaceuticals may lead to autoimmune diseases in experi-
mental animals or humans [Bigazzi, 1988; Kammuller et al.,
1989]. The consequences regarding the effects of immunosup-
pression/depression in humans have been extensively studied.
On the basis of epidemiological studies, a reduction in
resistance to infections produced by biological agents (virus,
bacteria, fungi) has been extensively described [Bowler et al.,
1997]. Neoplasia can also be the result of a compromised
surveillance mechanism on the part of the immune system
responsible for the elimination of neoplastic cells [Tryphonas
and Feeley, 2001]. Severe immunosuppression represents
a well-described risk factor for the development of non-Hodg-
kin’s lymphomas (NHL). An increase in incidence for NHL
was found in AIDS patients [Beral et al., 1991; Obrams
and Grufferman, 1991], and in patients that have had
immunosuppressive therapies following organ transplants
[Hoover and Fraumeni, 1973; Anonymous, 1984]. Conclusive
evidence is lacking, however, regarding risks associated with
factors that have a modest but prolonged capacity to induce
immunosuppression. Regarding chemical agents, there is some
epidemiological evidence that suggests that exposure to various
agents with a potential of immunotoxicity, for example,
pesticides and solvents, may be associated with an increase
in risk of NHL [Chiu and Weisenburger, 2003]. However, the
data is insufficient to support a causal relationship.
Immunotoxicity Testing
Due to the complexity of the immune system, the identi-
fication of substances that induce adverse effects on the
human immune system requires considering the markers
according to each specific immunologic effect.
Various organizations (Organization for Economic Co-
operation and Development, OECD, U.S. National Toxicol-
ogy Program, NTP, Dutch National Institute of Public and the
Environment, RIVM, US Food and Drug Administration,
FDA, U.S. Environmental Protection Agency, EPA) that
conduct testing for immunotoxicity have proposed different
approaches to immunotoxicity testing that include validated
immune testing protocols for both animals, as reviewed by
Luster et al. [1988] and Van Loveren and Vos [1989], and
humans, as reviewed by Tryphonas, 2001. OECD have pro-
posed guidelines for testing the toxicity of chemicals (guide-
line number 407) that were adopted in many countries.
Currently, there are a number of test procedures that
measure diverse immunological end points, mainly in labo-
ratory animals, but also in humans. Tiered testing schemes,
organized in stepwise protocols, have been successfully used
to identify and characterize immunotoxic substances. These
tests are designed to detect a change in the number of cells or
the weight of an immune system organ, or to evaluate altered
functionality of its components. Various agencies have
adopted protocols that include specific tests classified by
levels of increasing complexity. Level (or Tier) 1 is com-
prised of a series of preliminary tests that should indicate the
absence of toxicity to the immune system, or suggest a
direction for further study. The tests included in level (or
Tier) 2 are meant to enhance the understanding of the nature
of effect when level one tests are positive. Testing schemes
for establishing immunotoxicity in humans have also been
proposed [Colosio et al., 1999; Van Loveren et al., 1999]
according to a 3-tier approach. There is not always general
agreement, however, as to which tests fall into which levels.
In any case, it is agreed that the most effective approach to
immunotoxicity testing is to perform a battery of tests, and
interpret them in their entirety, not on the analysis of a single
parameter [Dean, 1979; Vos, 1980; Luster et al., 1988].
Objectives
The purpose of this study is to provide a documentation on
immunotoxicity of substances that are widely used in work
environment, by building tables for each chemical of interest
and the preparation of a matrix that includes information on the
immune category affected, the type of effect, and the strength
of evidence for each chemical, and subsequent scoring
the substances for their immunotoxicity evidence, power and
type of effect. It is intended to use the matrix in interpreting the
role of adverse immune effects of exposures to a variety of
industrial chemical compounds on the induction of different
diseases including neoplasms. The matrix will be used to
estimate relative risks by considering the immunotoxicity
evidence, the power and type of immunotoxic effect of each
agent to which an individual has been exposed in the context
of epidemiological studies, as the ‘‘Italian multicenter case-
control study on hematolymphopoietic malignancies in Italy
and exposures to solvents and pesticides’’ [Seniori Costantini
et al., 2001] where detailed information on chemical exposures
(intensity and probability) has been collected. Substances has
been selected on the basis of the number of workers exposed.
Currently only chemical compounds used in industrial settings
have been considered. Subsequently it is intended to take
pesticides into consideration as well.
MATERIALS AND METHODS
The first step was to prepare summary tables on im-
munotoxicity testing given the complexity of the immune
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system. A large part of information came from the Environ-
mental Health Criteria documents published by the World
Health Organization, ‘‘Principles and Methods for Assessing
Direct Immunotoxicity Associated with Exposure to Chemi-
cals’’ [International Programme on Chemical Safety [WHO,
1996], and ‘‘Principles and Methods for Assessing Hypersen-
sitization Associated with Exposure to Chemicals’’ [Interna-
tional Programme on Chemical Safety [WHO, 1999]. A
section of these texts provides an overview of the testing
strategies for detecting immunotoxicity adopted by various
organizations. These testing methods are discussed, often
with an evaluation of their efficacy. In constructing the tables,
these two texts were consulted to identify and describe test
characteristics and the immune response category that is
represented by each test. The report of validation study of
assessment of direct immunotoxicity in the rat by the Inter-
national Collaborative Immunotoxicity Study (ICICIS) group
investigators was also consulted in order to collect evaluation
of performance of various experimental techniques used in the
rats to indicate toxic effects on the immune system [ICICIS
Group Investigators, 1998]. This information has been up-
dated with more current information obtained from consulting
the web sites of the various organizations cited, when avail-
able, and with other information obtained by Medline searches
for immunotoxicity testing procedures.
In these summary tables, various tests that are used
in immunotoxicology research in animals and in humans are
summarized. They include, in addition to the principal
characteristics regarding each test, basic information on the
validation that each test has undergone regarding its ability to
determine adverse effects on the immune system. The follow-
ing information was included: (i) the immune category evalu-
ated by each test; (ii) specific test; (iii) organs, cells or other
parameters affected; (iv) principal effects on the immune
system; (v) organizations that recommend or mention the use
of these tests, and when considered, the level or tier attributed
to this test.
The second step consisted in the preparation of subs-
tance-specific tables for 20 substances of interest. Substances
were chosen on the basis of the most frequent chemicals
reported in the working histories of cases and controls en-
rolled and interviewed in the context of the ‘‘Multicenter
case-control study on hematolymphopoietic malignancies in
Italy.’’ For each substance the literature available was
reviewed and results were summarized taking into account
the type of immunotoxicity and strength of evidence
and power. The ‘‘substance tables’’ have been realized essen-
tially with the information collected from documents of
the Agency for Toxic Substances and Disease Registry
(ATSDR). In particular the paragraphs dealing with immu-
nological and lymphoreticular effects in the toxicological
profiles on the each substances have been considered. Other
information has been found from the environmental health
criteria (EHC) monographs and from ‘‘abstracts’’ and/or
from ‘‘full texts’’ of relevant papers through consultation of
‘‘Pubmed’’ and ‘‘Toxnet.’’
The third step was the classification of the 20 substances
of interest on the basis of the evidence of immunotoxicity,
expressed by end-points, considering the capacity of the tests
to predict the immunotoxicity (for instance: the effects on host
resistance weigh more heavily than effects on pathology). The
end-points have been identified on the basis of the existing
literature and indications supplied from an expert immuno-
toxicologist. Criteria to define evidence of immunotoxicity are
shown in Table I. An index was assigned in order to classify
different substances: strong, intermediate, weak, nil.
Substances with the same index of evidence (i.e., Ben-
zene, Trichloroethylene, Crystalline silica, and PHAs that
have all been classified ‘‘strong’’) were compared pair-wise
in order to produce a score for each chemical. Scoring was
TABLE I. Indexof Chemicals by Immunotoxic Evidence
Immunotoxic index Immunotoxic identification criteria (high predictability test)
Strong Host resistancea (viral, bacterial, parasite and tumoral model) and delayed type hypersensitivitya (DTH)
Host resistancea (viral, bacterial, parasite and tumoral model) andplaque forming cellsa (PFC)þcytotoxicT lymphocytea (CTL)
Host resistancea (viral, bacterial, parasite and tumoral model) and CTLaþ surfacemarker analysisb
Host resitstancea (viral, bacterial, parasite and tumoral model) and lymphoproliferative response (LPS)aþ (CTL)a
Intermediate Pathology1: Organ weight, histopathology cellularity, hematology (thymus, spleen, bonemarrow, lymph nodes) and delayed type hypersensiti-
vitya (DTH) (orMLR)a, and Natural Killer cell assaya (NK), and Plaque forming cellsa (PFC) (orAntigen specific antibody responses)a
Delayed type hypersensitivity (DTH)a (or mixed leukocyte response)a, and natural killer cell assay (NK)a, and plaque forming cells (PFC)a (or
Antigen specific antibody responses)
Weak Pathology: Organweight, histopathology cellularity, haematology (thymus, spleen, bonemarrow, lymph nodes) Surfacemarker analysisb
Surfacemarker analysisb (or cytochines, interleukins expression patterns)bmitogen responsea
Nil Toxicity but no immunotoxicity: Organweight, histopathology, cellularity, hematology of non immune tissue (i.e., liver, kidney)
aFunctional tests.
bNon-functional test.
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done considering doses (minimal doses at which the effects
are seen), but the route of administration was also considered
(main route of exposure). The number of positive studies and
of species (mice, rats, pigs, humans) was also taken into
account in scoring substances. Formally chemicals can be
adequately compared for their effects (comparable magni-
tude of effects and of doses that produce same effects) if
similar endpoints are compared and if tests are performed
under similar conditions and similar routes of exposure (i.e.,
inhalation compared with inhalation). This is not always
possible in a straightforward way, and experts have provided
further contributions.
Substances were classified also for the type of im-
munotoxic effects. The type of immunotoxic effect has been
assigned independently from the immunotoxic evidence.
This work has taken in consideration also those studies that
provide indications on the various types of immunotoxicity,
(as an example the test that finds the level and the type of
autoantibody provides information on alterations of auto-
immunity type). Several positive studies with highly predic-
tive tests for autoimmunity evaluation have been taken into
consideration, even if these tests are not always recom-
mended by the agencies for immunotoxicity evaluation. As
an example, crystalline silica has been classified as ‘‘strong,’’
because two tests (Host resistance and DHR) that satisfy
criteria of high predictability are positive. Its effects on the
immune system are mainly of autoimmunity. A document of
the U.S. FDA (FDA, 1999; Guidance for Industry and FDA
reviewers-Immunotoxicity testing) has used potential immu-
notoxic effects associated with immune responses to evalua-
tion of type of immunotoxic effect.
Criteria for classification of immune response associated
with potential immunotoxic effects are shown in Table II.
RESULTS
A total 321 studies were reviewed of which 227 were
animal studies and 94 human studies related to the 20
substances of interest. Human studies were related mainly to
crystalline silica and asbestos. Human studies included tests
on humoral and cellular mediated immunity (antibody levels
in serum or in fluid, surface marker analysis, cytokine syn-
thesis patterns, cytokine expression patterns, T- and B-cell
mitogen assay), and non-specific cellular mediated immunity
(NK cells activity: cytotoxicity, degranulation of granulo-
cytes: basophils or eosinophils), and test on autoimmunity
evaluation (autoantibodies titers in serum). Twenty tables
have been produced that include information collected for the
20 substances of interest. These tables include information on
the immune category evaluated by each test, organs, cells, or
other targets, principal effects on the immune system, doses,
routes of exposure for each specific assay. References for
each study and specific to the organizations that recommend
or mention the use of these tests, and, when considered, the TA
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level or tier attributed to this test, were also included. In Table
III a synthesis of the summary table for benzene is reported.
Benzene was classified as ‘‘strong’’ because the end points
affected (DTH and Host resistance). In Table IV the summary
evaluations for the 20 substances are shown. An index was
assigned on the basis of evidence of immunotoxicity and a
score on the basis of potency within the index of evidence
(defined by the dose, route of exposure and species). Subs-
tances were classified also on the basis of the specific
effect on the immune system, main type of immunosuppres-
sive effects with the ‘‘strong’’ and ‘‘intermediate’’ index, are
highlighted in the heavy type. Substances evaluated with
immunosuppressive effects and with ‘‘strong’’ and ‘‘inter-
mediate’’ index are: benzene, trichloroetylene, PHAs, wel-
ding fumes, asbestos, and styrene.
The test summary tables and the substance summary tables
are presented in Appendix A and B. These are available at http://
www.interscience.wiley.com/jpages/0271-3586/suppmat.
DISCUSSION
A matrix on immunotoxicity that can be used in epi-
demiological studies in which information on chemical
exposures has been constructed. This matrix can represent a
tool to identify chemicals with similar immunotoxic properties
and thus to improve risk estimations for immune-related
diseases. Information was systematically reviewed and
summarized. Weight of evidence (end points), doses to which
adverse effects were observed and type of immunotoxic effects
were considered in order to classify chemicals by their
immunotoxic potential. The presence of positive studies that
examined immunotoxicity in highly predictive tests provided
greater weight, as well as positive studies in human beings.
Limitations of this study include some discrepancies in
the results of studies on which the matrix is based. Some
effects of a given agent on immune function may result from
differences in the experimental system used by different
investigators and laboratories that generated the published
information examined (there can be significant variability in
some of these tests, from laboratory to laboratory), rather
than reflect real differences in the biological effects of these
toxic agents. There is a random aspect in the weight of evi-
dence: some substances may have been studied less broadly
or have gained less attention just by chance, selection of types
of studies depends on research group.
A second problem consists in the fact that different tests
have been performed for different chemicals in most cases,
making it difficult to compare substances. Moreover, most
chemicals tested can show more different types of immuno-
toxic effects (i.e., immunosuppression and stimulation),
depending on dose. Another problem is that conflicting
results for the same substances emerged for different end-
points depending on different doses, route of exposure,
species (human, animal).
Finally, the issue of potential differences in how toxic
agents may affect murine versus human immune systems is
raised. The proposed classification provides more infor-
mation than that usually offered by the current literature on
toxicity of chemicals as for immunotoxicants estimates risk
in epidemiological studies.
CONCLUSION
This matrix will be used in the ‘‘Multicenter case-control
study on hematolymphopoietic malignancies in Italy’’ to
estimate relative risks by considering the immunotoxicity
evidence and type of immunotoxic effects of each agent to
which individuals have been exposed. Cumulative exposure
to each chemical classified for its effect on immune system
will be estimated, in addition to peaks of exposure to strong
immunotoxic agents. Once validated the matrix will be made
available for other epidemiological studies in which
immunotoxicity of chemicals is of concern.
ABBREVIATIONS
NHL non-Hodgkin’s lymphomas
AIDS acquired immunodeficiency syndrome
ICICIS International Collaborative Immunotoxicity
Study
OECD Organization for Economic Co-operation
and Development
NTP U.S. National Toxicology Program
RIVM Dutch National Institute of Public Health
and the Environment
FDA U.S. Food and Drug Administration
EPA U.S. Environmental Protection Agency
NK natural killer
DTH delayed type hypersensitivity
PFC plaque forming cell
CTL cytotoxic T-lymphocyte
MLR mixed leucocyde response
LPS lipopolysaccharide
DMBA dimethylbenzanthracene
2-CP 2-chlorophenol
4-CP 4-chlorophenol
2,4-DCP 2,4-dichlorophenol
2,4,5-TCP 2,4,5-trichlorophenol
2,4,6-TCP 2,4,6-trichlorophenol
2,3,4,6-TeCP 2,3,4,6-tetrachlorophenol
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